Sage — Warburg and Crabtree Effects in Acute and Chronic Compensation

We are born with perfect biology. That is the first and most radical claim of the metabolic philosophy of medicine. Perfect for intermittent fuel availability, natural circadian entrainment, and the obligatory movement-strength hormesis that defined hominin life. What we label disease is, in the overwhelming majority of chronic cases, not a random error or a software bug in the genome. It is the predictable downstream consequence of a biology operating in chronic compensatory mode because its upstream ATP-generating capacity has been chronically compromised by mismatch. Acute compensation is life-saving. Chronic compensation becomes the pathology we name and attempt to suppress.

Recent work from the Seyfried laboratory (Duraj et al.) has usefully disentangled two related but non-identical phenomena that sit at the center of this compensatory logic: the Crabtree effect and the Warburg effect. Both involve increased reliance on substrate-level phosphorylation (SLP) when oxidative phosphorylation (OxPhos) is suppressed. They differ in duration, reversibility, and the degree of metabolic flexibility that remains. Placing these distinctions inside the broader metabolic philosophy of medicine clarifies how an acute, adaptive response becomes a locked-in driver of chronic disease.

Definitions and Experimental Distinctions

The Crabtree effect, first described in yeast and later observed in mammalian cells, is a glucose- and time-dependent suppression of OxPhos accompanied by increased glycolytic flux and ATP production through SLP. In non-tumor cells (for example, primary macrophages), the suppression is transient. Lowering glucose concentration or substituting respiratory fuels restores OxPhos capacity and sensitivity to mitochondrial inhibitors. The cell retains metabolic flexibility.

The Warburg effect, as classically described and as refined in contemporary tumor bioenergetics, is a persistent dependency on SLP (glucose and glutamine fermentation) even under oxygen-replete conditions. In dysregulated proliferating cells it is accompanied by lower metabolic flexibility under nutrient stress and sustained resistance to mitochondrial inhibitors. OxPhos insufficiency is not merely temporary; it has become the dominant steady-state phenotype.

Duraj and colleagues showed that OxPhos insufficiency is the primary bioenergetic hallmark of proliferating malignant cells, that dysregulated proliferation correlates with reduced flexibility, and that regulated proliferation in non-tumor cells can be sustained by OxPhos without a Warburg phenotype. The distinction is therefore not between “glycolysis versus respiration” as absolute categories, but between transient, reversible suppression and persistent, less flexible dependency.

Integration into the Metabolic Philosophy of Medicine

In the metabolic model, both effects are expressions of the same upstream constraint: insufficient ATP-generating capacity relative to load. When mitochondrial density, quality, or substrate oxidation cannot meet demand, cells upregulate emergency pathways that generate ATP through substrate-level phosphorylation. These pathways are ancestral; they predate the full efficiency of oxidative phosphorylation and remain available under hypoxic or substrate-variable conditions.

The Crabtree effect represents the acute, reversible end of this spectrum. High fermentable load or transient energetic strain suppresses OxPhos, shifts flux toward glycolysis, and preserves viability until the load is reduced or oxidative capacity is restored. This is compensatory and, within limits, adaptive.

The Warburg-like phenotype represents the chronic end of the same spectrum. When the shortfall in oxidative capacity persists—whether from chronic mismatch (fuel composition and timing, circadian disruption, absent hormesis), accumulating mitochondrial damage, or microenvironmental selection—the shift becomes less reversible. Metabolic flexibility declines. Natural selection within a heterogeneous cell population favors clones that can maintain biomass and survival on fermentable substrates. Epigenetic and signaling changes stabilize the new set-point. What began as an emergency program becomes the default operating mode.

This progression maps directly onto the ontology of the metabolic philosophy of medicine. Acute compensation is the system’s attempt to persist under temporary constraint. Chronic compensation is the same program running long enough to be reified as a named disease. The named syndromes—cancer, atherosclerosis, chronic inflammation, hypertension, glaucoma, macular degeneration, neurodegeneration—are visible clusters of these locked compensatory responses. The lipid-filled macrophage, the hyperinsulinemic hepatocyte, the neoplastic cell with fragmented mitochondria, and the underpowered retinal ganglion cell are not independent primary lesions; they are tissues whose ATP-generating headroom has been eroded and that have therefore shifted (for the retinal ganglion cell, on this hypothesis) toward more primitive, less flexible ATP generation.

Acute Processes: Crabtree-Like Compensation

In regulated or non-transformed cells, high glucose availability can suppress OxPhos and elevate glycolytic flux within hours. Macrophages and other immune effectors exhibit this pattern under inflammatory or substrate-rich conditions. The shift supports rapid ATP generation and effector functions when oxidative capacity is temporarily constrained. Because the underlying mitochondria remain competent, the phenotype reverses when glucose is lowered or respiratory fuels are supplied. Sensitivity to mitochondrial inhibitors returns. Flexibility is preserved.

Clinically, this corresponds to the early, reversible phase of many compensatory states: transient hyperglycemia after a carbohydrate load in a metabolically flexible individual, short-term inflammatory activation that resolves when the insult is cleared, or the initial response of endothelial or smooth-muscle cells to increased demand. The dashboard reading changes; the engine retains the capacity to return to baseline.

Chronic Processes: Warburg-Like Lock-In Across Disease

When oxidative capacity remains insufficient relative to ongoing load, the same shift loses reversibility. In cancer, this produces the classic Warburg phenotype: persistent SLP dependency, reduced flexibility, and selection for cells that thrive on glucose and glutamine. Oncogenes and tumor-suppressor alterations are frequently downstream or permissive of this bioenergetic state rather than its origin.

The identical logic operates, with tissue-specific expression, across the broader chronic disease cluster. In atherosclerosis, underpowered macrophages cannot maintain efficient efferocytosis and cholesterol efflux; they take up lipid as emergency fuel or buffer and become foam cells. The plaque is the histological record of chronic compensatory lipid handling in cells lacking sufficient ATP to perform housekeeping cleanly. In chronic inflammation and immune dysfunction, effector cells remain in a glycolytic, pro-inflammatory mode because resolution and precise orchestration are ATP-expensive and fail first. In hypertension, vascular remodeling and elevated pressure compensate for reduced efficiency of energy-dependent endothelial and smooth-muscle function. In the eye, retinal ganglion cells under chronic energy shortfall are more vulnerable to eye pressure and reduced blood flow, and trabecular meshwork cells under oxidative and mitochondrial stress drain fluid less well. On this hypothesis, raised eye pressure and progressive field loss may share an upstream energy shortfall with systemic hypertension. Animal studies support the cellular part of that picture; a shared cause in people has not been shown. In neurodegeneration, post-mitotic neurons with extreme energy demand shift toward less efficient ATP generation, impair proteostasis, and accumulate aggregates as parallel markers of energetic failure.

In each case the conventional model treats the most visible downstream manifestation as the disease to be suppressed. The metabolic model treats it as the chronic expression of an upstream ATP-generating constraint. The Crabtree-to-Warburg progression supplies the mechanistic bridge: what is reversible under acute, limited load becomes locked when the load is sustained and selection or metabolic memory stabilizes the new phenotype.

Mechanisms of Progression from Acute to Chronic

Three overlapping processes convert transient compensation into persistent pathology. First, sustained substrate overload or redox stress damages or reduces the mitochondrial population, lowering maximal oxidative capacity and making return to OxPhos more difficult. Second, within heterogeneous cell populations, natural selection favors variants that maintain viability and biomass under fermentable conditions; mutations that further impair OxPhos or enhance glycolytic and glutaminolytic flux gain fitness advantage. Third, epigenetic and signaling changes (including sustained mTOR activation, blunted AMPK and sirtuin tone, and altered transcription-factor networks) stabilize the glycolytic set-point, creating metabolic memory that outlasts the original trigger.

These mechanisms are not unique to cancer. They operate, at lower proliferative rates, in macrophages within plaques, in endothelial cells under chronic shear or glycemic stress, and in neurons under long-term energetic mismatch. The result is progressive loss of metabolic flexibility—the precise phenotype Duraj et al. associated with dysregulated rather than regulated proliferation.

Therapeutic Implications

Because the root constraint is insufficient oxidative ATP capacity relative to load, interventions that restore mitochondrial density, quality, and substrate flexibility address both the acute and chronic ends of the spectrum. Restricting fermentable substrates (properly formulated ketogenic or ancestral-pattern diets, time-restricted eating aligned with circadian cues) reduces the drive for Crabtree-like suppression and starves the persistent SLP dependency of Warburg-like states. Hormetic loading through resistance training and appropriate movement increases mitochondrial biogenesis and mitophagy, expanding oxidative headroom. Circadian realignment restores the oscillatory gating under which AMPK, sirtuins, and mTOR evolved to function. Targeted support for electron-transport efficiency (where clinically appropriate) can further reduce the need for compensatory fermentation.

These are not organ-specific treatments. They are persistence-supporting conditions that increase the probability that acute compensation remains reversible and that chronic lock-in is attenuated or partially reversed. In cancer, they align with Seyfried’s emphasis on metabolic therapy that exploits reduced flexibility. In the wider chronic disease cluster, they target the shared upstream driver rather than each downstream dashboard reading in isolation.

Conclusion

The Crabtree and Warburg effects are not competing explanations. They are temporally and mechanistically related expressions of the same compensatory response to insufficient mitochondrial ATP-generating capacity. The former is the acute, reversible form seen in metabolically competent cells under temporary load. The latter is the persistent form that emerges when the shortfall continues, flexibility declines, and selection or memory locks the phenotype in place.

Within the metabolic philosophy of medicine, this distinction supplies precision without fragmenting the unifying claim. Chronic disease is the visible summation of compensatory modes that began as adaptive responses to bioenergetic constraint. Restoring the conditions under which ancestral biology can again generate sufficient ATP without constant emergency signaling does not merely lower individual risk markers. It reduces the drive for both the transient and the locked forms of the shift. The engine, not the dashboard, remains the proper target.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 23, 2026.

See the notice at the top of this page. Working hypothesis, not medical advice.